Log In
BCIQ
Print this Print this
 

MB-102

  Manage Alerts
Collapse Summary General Information
Company Mustang Bio Inc.
DescriptionChimeric antigen receptor (CAR) T cells targeting interleukin-3 (IL-3) receptor alpha (CD123)
Molecular Target Interleukin-3 (IL-3) receptor alpha (CD123)
Mechanism of Action 
Therapeutic ModalityCell therapy: Non-stem cell
Latest Stage of DevelopmentPhase I
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat relapsed or refractory acute myeloid leukemia (AML)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today